Bull World Health Organ. 1983;61(5):731-44.
The evidence for an association between the carrier state of hepatitis B virus infection and hepatocellular carcinoma (liver cell cancer) is now sufficiently strong to justify the use of a vaccine against this infection as a means of preventing this cancer. Effective vaccines are available and have been tested in feasibility studies, and their use in field trials to test their effectiveness against the long-term risk of developing this cancer is now possible. At the present time, only limited quantities of the vaccine derived from human plasma infected by the hepatitis B virus are available, and the development of other types of vaccine is discussed together with the necessary revision of the present requirements for vaccine production. As the studies to assess the prevention of this cancer would require the surveillance of subjects for some years, consideration is also given to the design of field studies with short- and medium-term objectives.
乙肝病毒感染携带者状态与肝细胞癌（肝癌）之间存在关联的证据现已足够有力，足以证明使用针对这种感染的疫苗作为预防这种癌症的一种手段是合理的。有效的疫苗已经有了，并且已经在可行性研究中进行了测试，现在有可能在现场试验中使用它们来测试其预防这种癌症长期风险的有效性。目前，仅可获得有限数量的源自感染乙肝病毒的人血浆的疫苗，同时还讨论了其他类型疫苗的研发以及对当前疫苗生产要求的必要修订。由于评估这种癌症预防效果的研究需要对受试者进行数年的监测，因此也考虑了具有短期和中期目标的现场研究设计。
